menu
    • menu
    [{"orgOrder":0,"company":"4TEEN4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2025","type":"Series C Financing","leadProduct":"Procizumab","moa":"cDPP3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"4TEEN4 Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"4TEEN4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4TEEN4 Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by 4TEEN4 Pharmaceuticals

    Menu

    4TEEN4 Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            4TEEN4 Pharmaceuticals

                            Germany arrow
                            CTAD25
                            Not Confirmed

                            4TEEN4 Pharmaceuticals

                            Germany arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Procizumab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $64.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            4TEEN4 Extends Series C to €55M for Procizumab in Cardiogenic Shock Clinical Development

                            Details : The Series C financing for Procizumab, an unconjugated antibody targeting cDPP3, will support the development of treatments for cardiogenic shock.

                            Product Name : AK1967

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            November 13, 2025

                            Lead Product(s) : Procizumab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $64.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth